Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enlivex Therapeutics Ltd. (ENLV : NSDQ)

• Company Description    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. Number of Employees: 36

• Price / Volume Information    Yesterday's Closing Price: $1.34 Daily Weekly Monthly 20 Day Moving Average: 127,274 shares Shares Outstanding: 23.65 (millions) Market Capitalization: $31.69 (millions) Beta: 0.79 52 Week High: $1.76 52 Week Low: $0.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 42.55% 37.22% 12 Week 55.81% 31.06% Year To Date 14.53% 7.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 14 Einstein Street - Ness Ziona,L3 7403618 ISR ph: 972-2620-8072 fax: 972-2620-8070 info@enlivexpharm.com http://www.enlivex.com

• General Corporate Information    Officers Oren Hershkovitz - Chief Executive Officer Shai Novik - Executive Chairman Roger Pomerantz - Director and Vice Chairman Shachar Shlosberger - Chief Financial Officer Gili Hart - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M4130Y106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/29/25 Share - Related Items Shares Outstanding: 23.65 Most Recent Split Date: 3.00 (0.13:1) Beta: 0.79 Market Capitalization: $31.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/29/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 31.82% vs. Previous Quarter: 34.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -57.67 12/31/24 - -56.88 ROA 06/30/25 - - 03/31/25 - -50.52 12/31/24 - -49.87 Current Ratio 06/30/25 - - 03/31/25 - 7.20 12/31/24 - 6.84 Quick Ratio 06/30/25 - - 03/31/25 - 7.20 12/31/24 - 6.84 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.87 12/31/24 - 1.00 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©